Sonic Healthcare Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SKHCF research report →
Price Chart
About the company
Sonic Healthcare Limited delivers medical diagnostic services to a diverse clientele, including medical professionals, hospitals, public health organizations, and individual patients. The company's services encompass a broad spectrum of laboratory medicine and pathology testing, covering biochemistry, cytopathology, genetics, haematology, histopathology, immunoserology, microbiology, molecular pathology, prenatal diagnostics, toxicology, and other related functions. Furthermore, Sonic provides extensive radiology services, such as magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, X-ray, mammography, nuclear medicine, PET CT, interventional procedures, and bone mineral densitometry.
- CEO
- James Pacey Newcombe
- IPO
- 2010
- Employees
- 49,000
- HQ
- Sydney, NSW, AU
Get TickerSpark's AI analysis on SKHCF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $6.84B
- P/E
- 17.60
- Fwd P/E
- 11.76
- PEG
- 1.18
- P/S
- 0.98
- P/B
- 1.28
- EV/EBITDA
- 8.12
- Div Yield
- 4.99%
- Gross Margin
- 27.65%
- Op Margin
- 9.92%
- Net Margin
- 5.56%
- ROE
- 7.20%
- ROIC
- 5.63%
Latest fiscal year · YoY change
- Revenue
- $10.93B+13.4%
- Gross Profit
- $3.02B-5.2%
- Op Income
- $1.08B
- Net Income
- $607.44M+18.3%
- EPS
- $1.23+15.0%
- OCF Growth
- +8.2%
- FCF Growth
- -19.5%
- 52W High
- $16.10
- 52W Low
- $11.67
- 50D MA
- $13.27
- 200D MA
- $13.86
- Beta
- 0.59
- RSI (14)
- 69
- Avg Volume
- 214
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Sonic Healthcare delivered solid FY 2026 results with strong revenue and earnings growth, while guiding to continued FY 2027 growth despite regulatory and integration headwinds.· August 19, 2026
- FY 2026 revenue rose 13% to AUD 10.867 billion and EBITDA increased 11% to AUD 1.933 billion, with EPS up 14% to AUD 1.26.
- Organic revenue growth was 5%, led by advanced diagnostics, Australian pathology specialist referrals, and strong momentum in Germany and Switzerland.
- Management highlighted progress on the U.S. operating review, which is expected to add AUD 25 million to AUD 30 million to FY 2027 earnings.
- FY 2027 EBITDA guidance is AUD 1.95 billion to AUD 2.03 billion on a constant-currency basis, excluding about AUD 30 million of back-office IT transformation costs.
- Capital allocation remains focused on investment-grade balance sheet strength, dividends, selective acquisitions, and possible share buybacks.
FY 2026 total revenue increased 13% to AUD 10.867 billion. EBITDA rose 11% to AUD 1.933 billion, or AUD 1.916 billion on a constant-currency basis, and was within guidance. Net profit after tax increased 17% to AUD 621 million, with EPS up 14% to AUD 1.26. The underlying effective tax rate was 26%, depreciation was AUD 771 million, interest expense was AUD 188 million, and property plant and equipment CapEx totaled AUD 631 million, including AUD 280 million of strategic property investments. Non-recurring items resulted in an approximately AUD 51 million EBITDA adjustment. For FY 2027, management guided to EBITDA of AUD 1.95 billion to AUD 2.03 billion on a constant-currency basis, excluding approximately AUD 30 million of IT transformation costs; depreciation is expected at AUD 810 million to AUD 825 million, amortization at AUD 90 million to AUD 95 million, interest expense up 6%, and tax rate around 27%.
Jim Newcombe framed the quarter as proof of Sonic’s scale-and-mix strategy, emphasizing medical leadership, operational excellence, and long-term trust with doctors and patients. He pointed to strong momentum in advanced diagnostics, continued synergy capture in Germany and Switzerland, and internal operating reviews in the U.S. as key levers for improving EPS and ROIC. His tone was confident and constructive, while acknowledging that some markets face regulatory or integration pressure.
Chris Wilks focused on the reported financials and the bridge to FY 2027. He detailed the AUD 10.867 billion revenue base, AUD 1.933 billion EBITDA, AUD 621 million NPAT, and AUD 1.26 EPS, then walked through the main cost items including AUD 771 million depreciation, AUD 188 million interest, and AUD 631 million CapEx. He said the balance sheet remains investment-grade with a debt cover ratio of 2.2 and approximately AUD 1.6 billion of headroom before the final dividend, and reiterated capital priorities: progressive dividends, selective acquisitions, and potential buybacks.
Analysts focused on why FY 2027 EBITDA growth appears modest, with questions about the biggest drivers, the U.S. turnaround, FX, and whether organic growth is slowing. Management said the main drivers remain organic growth, U.S. efficiency gains, and synergy capture in Switzerland and Germany, while noting that Swiss fee cuts and the U.K. HWE contract timing are the main drag on near-term leverage. They also said the U.S. operating review is producing tangible savings, PAMA cuts are excluded from guidance, and ZYPPIN benefits are still building after a more complex rollout than expected.
The bull case is that Sonic still posted strong top-line and earnings growth in FY 2026 while growing organically 5% across a diversified portfolio. Management sounded confident that advanced diagnostics, U.S. efficiency measures, and ongoing synergy capture in Germany and Switzerland can support further earnings growth over time. The company also has a sizable digital transformation and capital management program aimed at improving productivity and returns.
The main risks are that FY 2027 growth is being held back by fee cuts in Switzerland, delayed margin ramp in the U.K., and uncertainty around U.S. PAMA reimbursement cuts. Management also flagged rising interest expense, higher FY 2027 IT transformation costs, and some margin pressure from labor and integration issues in certain markets. The U.S. business, while improving, was still described as below where management wants it to be.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 92.7%
- Shares Outstanding
- 494.24M
- Float Shares
- 457.96M
Our SKHCF coverage
Recent articles, reports, and earnings notes.
No research on SKHCF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SKHCF report →Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.